Peng Xueqiang, Fang Jianjun, Lou Chuyuan, Yang Liang, Shan Shaobo, Wang Zixian, Chen Yutong, Li Hangyu, Li Xuexin
Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China.
Department of Ophthalmology, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an 710004, China.
Acta Pharm Sin B. 2024 Aug;14(8):3432-3456. doi: 10.1016/j.apsb.2024.05.010. Epub 2024 May 13.
The advent of cancer immunotherapy has imparted a transformative impact on cancer treatment paradigms by harnessing the power of the immune system. However, the challenge of practical and precise targeting of malignant cells persists. To address this, engineered nanoparticles (NPs) have emerged as a promising solution for enhancing targeted drug delivery in immunotherapeutic interventions, owing to their small size, low immunogenicity, and ease of surface modification. This comprehensive review delves into contemporary research at the nexus of NP engineering and immunotherapy, encompassing an extensive spectrum of NP morphologies and strategies tailored toward optimizing tumor targeting and augmenting therapeutic effectiveness. Moreover, it underscores the mechanisms that NPs leverage to bypass the numerous obstacles encountered in immunotherapeutic regimens and probes into the combined potential of NPs when co-administered with both established and novel immunotherapeutic modalities. Finally, the review evaluates the existing limitations of NPs as drug delivery platforms in immunotherapy, which could shape the path for future advancements in this promising field.
癌症免疫疗法的出现通过利用免疫系统的力量，对癌症治疗模式产生了变革性影响。然而，如何实际且精确地靶向恶性细胞这一挑战依然存在。为了解决这一问题，工程化纳米颗粒（NPs）因其尺寸小、免疫原性低且易于进行表面修饰，已成为免疫治疗干预中增强靶向药物递送的一种有前景的解决方案。这篇综述深入探讨了纳米颗粒工程与免疫疗法交叉领域的当代研究，涵盖了广泛的纳米颗粒形态以及为优化肿瘤靶向和提高治疗效果而定制的策略。此外，它强调了纳米颗粒用于绕过免疫治疗方案中遇到的众多障碍的机制，并探究了纳米颗粒与既定和新型免疫治疗方式联合使用时的综合潜力。最后，该综述评估了纳米颗粒作为免疫疗法中药物递送平台的现有局限性，这可能为这一充满前景的领域未来的发展指明方向。
